<?xml version='1.0' encoding='utf-8'?>
<document id="23782582"><sentence text="Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration."><entity charOffset="76-83" id="DDI-PubMed.23782582.s1.e0" text="digoxin" /></sentence><sentence text="This study was conducted in order to assess the effect of multiple doses of odanacatib, a cathepsin (Cat)-K inhibitor, on the pharmacokinetics of digoxin"><entity charOffset="76-86" id="DDI-PubMed.23782582.s2.e0" text="odanacatib" /><entity charOffset="146-153" id="DDI-PubMed.23782582.s2.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23782582.s2.e0" e2="DDI-PubMed.23782582.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23782582.s2.e0" e2="DDI-PubMed.23782582.s2.e1" /></sentence><sentence text="" /><sentence text="Twelve healthy male and female subjects received 0" /><sentence text="5 mg digoxin and 50 mg odanacatib"><entity charOffset="5-12" id="DDI-PubMed.23782582.s5.e0" text="digoxin" /><entity charOffset="23-33" id="DDI-PubMed.23782582.s5.e1" text="odanacatib" /><pair ddi="false" e1="DDI-PubMed.23782582.s5.e0" e2="DDI-PubMed.23782582.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23782582.s5.e0" e2="DDI-PubMed.23782582.s5.e1" /></sentence><sentence text="" /><sentence text="This open label study was conducted to determine the effect of odanacatib on the plasma pharmacokinetics of immunoreactive digoxin"><entity charOffset="63-73" id="DDI-PubMed.23782582.s7.e0" text="odanacatib" /><entity charOffset="123-130" id="DDI-PubMed.23782582.s7.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23782582.s7.e0" e2="DDI-PubMed.23782582.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23782582.s7.e0" e2="DDI-PubMed.23782582.s7.e1" /></sentence><sentence text=" Subjects received a single oral dose of 0" /><sentence text="5 mg digoxin followed by a 10-day washout, followed by 3 once-weekly oral doses of 50 mg odanacatib and co-administration with 0"><entity charOffset="5-12" id="DDI-PubMed.23782582.s9.e0" text="digoxin" /><entity charOffset="89-99" id="DDI-PubMed.23782582.s9.e1" text="odanacatib" /><pair ddi="false" e1="DDI-PubMed.23782582.s9.e0" e2="DDI-PubMed.23782582.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23782582.s9.e0" e2="DDI-PubMed.23782582.s9.e1" /></sentence><sentence text="5 mg digoxin with the last odanacatib dose"><entity charOffset="5-12" id="DDI-PubMed.23782582.s10.e0" text="digoxin" /><entity charOffset="27-37" id="DDI-PubMed.23782582.s10.e1" text="odanacatib" /><pair ddi="false" e1="DDI-PubMed.23782582.s10.e0" e2="DDI-PubMed.23782582.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23782582.s10.e0" e2="DDI-PubMed.23782582.s10.e1" /></sentence><sentence text=" A linear mixed-effect model was used to analyze AUC0-120h" /><sentence text=" Safety and tolerability were assessed" /><sentence text="" /><sentence text="The estimated geometric-mean-ratio (90% confidence interval) for AUC0-120h was 0" /><sentence text="95 (0" /><sentence text="89, 1" /><sentence text="01), which was within (0" /><sentence text="80, 1" /><sentence text="25) determined to demonstrate a lack of interaction" /><sentence text=" There were no serious AEs, discontinuations due to AEs, or clinically significant abnormalities in ECG or vital sign measurements" /><sentence text="" /><sentence text="This study demonstrated that 50 mg odanacatib did not lead to clinically important effects on the pharmacokinetics of 0" /><sentence text="5 mg digoxin"><entity charOffset="5-12" id="DDI-PubMed.23782582.s23.e0" text="digoxin" /></sentence><sentence text="" /></document>